Concizumab (Anti-TFPI)

Synonyms: NN 7415, mAb 2021, Anti-TFPI Recombinant Antibody

Concizumab (Anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. MW : 145.5 KD.

Concizumab (Anti-TFPI)

Purity & Quality Control

≥99

Biological Activity

Description Concizumab (Anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. MW : 145.5 KD.

Product Details

CAS No. 1312299-39-0
Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac,pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Concizumab (Anti-TFPI) | Concizumab (Anti-TFPI) supplier | purchase Concizumab (Anti-TFPI) | Concizumab (Anti-TFPI) cost | Concizumab (Anti-TFPI) manufacturer | order Concizumab (Anti-TFPI) | Concizumab (Anti-TFPI) distributor